AI-generated summary
The authors reviewed 13 randomized clinical trials of preventive photobiomodulation in patients receiving chemotherapy, pooling 828 patients. They report that 40.94% developed oral mucositis, with fewer cases in the photobiomodulation group (128) than in the control group (211), and conclude the treatment was effective at reducing mucositis. Most included studies were rated low risk of bias.
- Participants
- 828
- Studies included
- 13
- Who or what was studied
- Patients aged 1 to 84 years receiving chemotherapy, excluding those previously treated with radiation therapy
- Limits stated in the abstract
- The abstract does not report wavelengths, doses or protocol details, and the pooled studies vary in design and population.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background/Objectives
Oral mucositis (OM) is the most common acute complication among cancer patients. It initially manifests as an inflammatory process, beginning with erythema and edema of the oral mucosa, progressing to erosive lesions, and ultimately leading to highly painful ulcers. This systematic review seeks to evaluate the efficacy of preventive PBM protocols in mitigating chemotherapy-induced OM.
Methods
The PRISMA guidelines were followed. The search was conducted in August 2024 in the following databases: Pubmed/Medline, Scopus, WoS, Cochrane, SciELO, BDTD, and BVS/IBECS. Only randomized clinical trials that utilized preventive photobiomodulation protocols in chemotherapy patients were included. All studies involving patients previously treated with radiation therapy were excluded. The Joanna Briggs Institute tool was employed for risk of bias analysis.
Results
The total sample size consisted of 828 patients aged between 1 and 84 years. There was no predisposition based on gender or age. When the patients were evaluated under preventive protocols, some cases of mucositis manifested in a total of 339 cases. Of the total number of patients in the 13 selected studies (n = 828), 40.94% developed oral mucositis over the course of chemotherapy cycles. Comparing the experimental and control groups, 211 patients who did not receive preventive laser treatment developed oral mucositis; in contrast, only 128 in the experimental group did. Eighty-five percent of the studies exhibited a low risk of bias.
Conclusions
Preventively applied photobiomodulation proves effective in minimizing or even preventing the manifestation of oral mucositis and reducing the severity of lesions that arise during oncological treatment. Registration PROSPERO (CRD42023465329).
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Oral mucositis, Photobiomodulation, Systematic review, Risk of bias, Sample size, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.